Companies Dominating the Thiazide Diuretics Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Sanofi
- Bayer AG
- Centaur Pharmaceuticals Private Limited
- Validus Pharmaceuticals LLC
- Teva Pharmaceutical Industries Ltd.
- Novartis Pharmaceuticals Corporation
- Boehringer Ingelheim International GmbH
- Cipla Inc.
- scPharmaceuticals, Inc.
Browse Key Market Insights with Data Illustration:
In the News
- December,2021- Arena Pharmaceuticals, Inc. and Pfizer Inc. announced that they had reached a final agreement whereby Pfizer will purchase Arena, a clinical stage business creating novel therapeutic treatments for the management of several immuno-inflammatory illnesses. Pfizer will purchase all of Arena's outstanding shares under the terms of the agreement for $100 per share in an all-cash deal, for a total equity value of roughly $6.7 billion. Both firms' boards of directors have overwhelmingly approved the deal.
- May,2019- In order to promote clinical research in pulmonary hypertension (PH), with an emphasis on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), Bayer U.S. announced the creation of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards. Over the course of a two-year cycle, the initiative will provide grants totaling up to $1 million.
